This announcement is a separate document:
アステラス製薬：PADCEV（エンホルツマブ ベドチン） 進行性尿路上皮がん患者の一次治療を対象とした ペムブロリズマブとの併用療法について 欧州 CHMP が販売承認勧告を採択
Astellas Pharma: European index CHMP has adopted a sales approval recommendation for the combination therapy with Pemprolizumab targeting primary treatment of advanced urothelial cancer patients with PADCEV (enfortumab vedotin).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.